[Investigation of HGV infection in various populations in Guangxi].
In order to understand the situation of HGV infection in various populations in Liuzhou prefecture of Guangxi, Zhuangzu Autonomous Region, and also to compare the HGV, HBV, HCV infections between intravenous drug abusers and healthy persons (those for physical examination, the same below), the anti-HGV, -HCV and HBVM (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) were detected by ELA and, besides, tested further the 20 anti-HGV seropositive cases for HGV-RNA by RT-nPCR. The results showed that in the populations tested, the HGV seropositive rate was 9.8% (106/1079), separately they were 23.8% (5/21), 21.1% (23/109), 12.5% (6/48), 12.0% (6/50), 12.0% (20/166), 9.3% (3/32), 8.2% (34/413), 4.3% (6/140), and 3.0% (3/100) in liver cirrhosis, intravenous drug abusers, repeated blood and blood products transfused patients, hepatocellularcarcinoma patients, viral hepatitis, haemodialysis patients, healthy persons, paid blood donors and healthy pregnant women respectively. In intravenous drug abusers, the HGV, HBV, HCV infection rate were 21.2% (23/109), 75.3% (82/109) and 7.3% (8/109) respectively, while they were 8.2% (9/109), 20.1% (22/109), and 1.8% (2/109) in healthy persons respectively. These data showed that Liuzhou prefecture of Guangxi was HGV high epidemic area, HGV infection rate was higher in populations of intravenous drug abusers, viral hepatitis, liver cirrhosis and repeatedly blood and blood products transfused patients, even in pregnant women the HGV infection also occurred. There was a significant difference of HGV, HBV, HCV infection rates between intravenous drug abusers and healthy persons (P < 0.005).
Ru
H
H
People's Hospital of Liuzhou City, Liuzhou 545001.
Wen
X
X
Liang
W
W
D000328:Adult; D002681:China / Q000453:epidemiology; D005260:Female; D018178:Flaviviridae Infections / Q000453:epidemiology* / Q000821:virology; D029407:GB virus C / Q000235:genetics / Q000302:isolation & purification*; D006509:Hepatitis B / Q000453:epidemiology; D006526:Hepatitis C / Q000453:epidemiology; D006525:Hepatitis, Viral, Human / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D008297:Male; D015995:Prevalence; D012367:RNA, Viral / Q000097:blood*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016036:Seroepidemiologic Studies; D015819:Substance Abuse, Intravenous; D015163:Superinfection / Q000821:virology
D012367:RNA, Viral